Biodexa Pharmaceuticals Plc
NASDAQ · us_market
No AI summary generated yet for this ticker.
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
European equities traded in the US as American depositary receipts were rising late Friday morning,
European equities traded in the US as American depositary receipts were rising late Friday morning,
European equities traded in the US as American depositary receipts were trending slightly lower late
European equities traded in the US as American depositary receipts were trending slightly lower late
European equities traded in the US as American depositary receipts were trending higher late Tuesday
European equities traded in the US as American depositary receipts were trending higher late Tuesday
European equities traded in the US as American depositary receipts were trending slightly higher lat
European equities traded in the US as American depositary receipts were trending slightly higher lat
European equities traded in the US as American depositary receipts rose Wednesday with the S&P Europ
European equities traded in the US as American depositary receipts rose Wednesday with the S&P Europ
European equities traded in the US as American depositary receipts were trending lower late Tuesday
European equities traded in the US as American depositary receipts were trending lower late Tuesday
European equities traded in the US as American depositary receipts were heading higher late Monday m
European equities traded in the US as American depositary receipts were heading higher late Monday m
European equities traded in the US as American depositary receipts were sharply lower late Friday mo
European equities traded in the US as American depositary receipts were sharply lower late Friday mo
May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company’s share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage owners
European equities traded in the US as American depositary receipts were little changed late Wednesda
European equities traded in the US as American depositary receipts were little changed late Wednesda
European equities traded in the US as American depositary receipts opened the week on a flat note Mo
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2020-09-09 | -200000.00 | -44000.00 | +78.00% |
| 2020-06-14 | -6000000.00 | -8500000.00 | -41.67% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BDRX | +14.52% | -26.56% | -69.43% | -93.57% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +11.55% | -21.92% | -65.98% | -106.26% |